10 March 2025 : Clinical Research
NSTEMI Risk Prediction with the Combination of the Biomarkers Epicardial Adipose Tissue and Soluble Suppression of Tumorigenicity 2
Jiayu Yin1ACEFG, Bowen Qiu2BCEF, Tingting Li1CE, Yifei Tao3ADE*, Xiaosong Gu1AGDOI: 10.12659/MSM.947019
Med Sci Monit 2025; 31:e947019
Table 1 Patient characteristics.
| MACEs (n=59) | Non-MACEs (n=376) | P value | |
|---|---|---|---|
| Age, years | 60.54±11.17 | 57.73±7.62 | 0.014 |
| Male, n (%) | 28 (47.46) | 149 (39.63) | 0.255 |
| Body mass index, kg/m | 25.00±3.21 | 24.88±3.33 | 0.805 |
| Current smoker, n (%) | 33 (55.93) | 189 (50.27) | 0.418 |
| Diabetes, n (%) | 26 (44.07) | 121 (32.18) | 0.073 |
| Hypertension, n (%) | 29 (49.15) | 173 (46.01) | 0.653 |
| Systolic blood pressure, mmHg | 122.41±18.82 | 124.35±15.15 | 0.378 |
| Diastolic blood pressure, mmHg | 75.08±11.38 | 76.33±13.74 | 0.447 |
| Heart rate, bpm | 79.14±11.64 | 77.94±12.78 | 0.499 |
| Total cholesterol, mmol/L | 4.87±1.68 | 4.64±1.39 | 0.240 |
| Triglycerides, mmol/L | 1.80±1.02 | 1.70±1.13 | 0.524 |
| HDL cholesterol, mmol/L | 1.29±0.39 | 1.34±0.45 | 0.433 |
| LDL cholesterol, mmol/L | 2.71±1.15 | 2.63±1.02 | 0.616 |
| Peak hsCRP, mg/L | 50.65±64.44 | 37.71±53.80 | 0.096 |
| Peak hsTnT, ng/L | 3359.0 (1400.0, 4847.5) | 2435.0 (847.1, 4052.3) | 0.018 |
| Peak NT-proBNP, pg/mL | 1213.0 (271.4, 3321.2) | 1143.0 (453.1, 2580.3) | 0.584 |
| Killip class ≥2, n (%) | 15 (25.42) | 53 (14.10) | 0.391 |
| TIMI ≤1, n (%) | 53 (89.83) | 298 (79.26) | 0.056 |
| LAD, n (%) | 30 (50.85) | 186 (49.47) | 0.844 |
| LCX, n (%) | 4 (6.78) | 51 (13.56) | 0.145 |
| RCA, n (%) | 25 (42.37) | 139 (36.97) | 0.426 |
| Statin, n (%) | 56 (94.92) | 346 (92.02) | 0.606 |
| SGLT-2, n (%) | 5 (8.47) | 53 (14.10) | 0.238 |
| ACEI/ARB/ARNI, n (%) | 24 (40.68) | 159 (42.29) | 0.816 |
| β-blockers, n (%) | 42 (71.19) | 297 (78.99) | 0.179 |
| Spironolactone, n (%) | 9 (15.25) | 48 (12.77) | 0.598 |
| sST2, ng/mL | 67.46±24.46 | 51.23±27.57 | <0.001 |
| LV ejection fraction, % | 49.54±4.60 | 52.31±4.66 | <0.001 |
| EAT (mL) | 87.79±25.05 | 72.40±19.35 | <0.001 |
| EAT index (mL/m) | 48.88±9.74 | 41.37±11.70 | <0.001 |
| MACEs – major adverse cardiac events; HDL-C – high-density lipoprotein cholesterol; LDL-C – low-density lipoprotein cholesterol; hsCRP – high-sensitivity C reactive protein; hsTnT – high-sensitivity cardiac troponin T; NT-proBNP – N terminal pro B type natriuretic peptide; sST2 – soluble suppression of tumorigenicity 2; LV – left ventricular; EAT – epicardial adipose tissue; SGLT-2 – sodium-dependent glucose transporters 2; ACEI – angiotensin-converting enzyme inhibitors; ARB – angiotensin receptor blocker; ARNI – angiotensin receptor-neprilysin inhibitor. | |||